论文部分内容阅读
目的:探讨金茵颗粒剂抗豚鼠胆色素结石性胆囊炎的分子机制。方法:构建豚鼠胆色素结石性胆囊炎模型,然后用金茵颗粒剂连续治疗15 d。治疗结束后,采用酶联免疫吸附法(ELISA)检测血清、胆汁中前列腺素E2(prostaglandin E2,PGE2)的含量,免疫组化法检测胆囊组织内环氧化酶-2(cycloxygenase-2,COX-2)和核因子-κB(nuclear factor-kappa B,NF-κB)的表达量及活化细胞数量。结果:与模型对照组比较,金茵颗粒剂治疗组豚鼠血清和胆汁中PGE2的含量以及胆囊组织内COX-2和NF-κB的表达量及活化细胞数量明显减少,有统计学显著差异(P<0.01)。结论:金茵颗粒剂治疗胆囊炎可能的分子机制是通过抑制NF-κB的活化及表达量进而抑制COX-2的表达和PGE2的合成。
Objective: To investigate the molecular mechanism of Jin Yin Granule in guinea pig gallstone cholecystitis. Methods: The model of cholecystolithiasis was established in guinea pigs, and then treated continuously with Jin Yin Granules for 15 days. After the treatment, the level of prostaglandin E2 (PGE2) in serum and bile was detected by enzyme linked immunosorbent assay (ELISA), the expression of cyclooxygenase-2 (COX- 2) and nuclear factor-kappa B (NF-κB) expression and the number of activated cells. Results: Compared with the model control group, the content of PGE2 and the expression of COX-2 and NF-κB and the number of activated cells in the serum and bile of the guinea pigs treated with Jinyin Granules obviously decreased (P <0.01). Conclusion: The possible molecular mechanism of Jin Yin Granules in treating cholecystitis is to inhibit the expression of COX-2 and the synthesis of PGE2 by inhibiting the activation and expression of NF-κB.